Situation: A 52-year-old woman has invasive ductal carcinoma of the left breast, stage IIB (T2 N1 M0), grade 3, estrogen receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative. She undergoes a modified radical mastectomy with axillary lymph node dissection and will then receive doxorubicin and cyclophosphamide every 21 days. She has no known drug allergies. During a peripheral intravenous push of doxorubicin, she reports burning at the site, which is swollen, and there is no blood return. The nurse has completed the initial extravasation steps, and dexrazoxane is ordered per protocol. How should the nurse use compresses?

Doxorubicin is an anthracycline vesicant. Anthracycline extravasation is treated with cold compresses, which limit spread of the drug, and dexrazoxane is its antidote. Protocols require the cold packs to be removed at least 15 minutes before dexrazoxane is given.

Understanding the clinical situation

The patient is receiving doxorubicin, an anthracycline antibiotic classified as a vesicant. Vesicants can cause severe tissue necrosis if they leak outside the vein. The reported burning, swelling, and absence of blood return confirm extravasation. The nurse has already stopped the infusion, aspirated residual drug, and removed the catheter as initial steps. Now the focus shifts to local thermal management and antidote administration.

Why cold compresses are used for anthracycline extravasation

Cold application causes local vasoconstriction, which limits the spread of doxorubicin into surrounding tissue and slows cellular uptake of the drug. This reduces the area of potential necrosis and helps contain the injury. The European Oncology Nursing Society guideline specifically recommends topical cooling for anthracycline extravasations, distinguishing this approach from the topical heating used for plant alkaloid vesicants such as vincristine or vinblastine ^[3].

Key point! The thermal intervention is drug-class specific. Anthracyclines require cold; plant alkaloids require heat. Reversing this can worsen tissue damage.

The role of dexrazoxane and the timing of cold removal

Dexrazoxane is the specific antidote for anthracycline extravasation. It works by binding to iron and preventing the formation of free radicals that mediate doxorubicin-induced tissue injury. For dexrazoxane to distribute effectively into the affected tissue, local blood flow must be adequate.

Protocols require cold packs to be removed at least 15 minutes before dexrazoxane infusion begins. If cold packs remain in place during the infusion, persistent vasoconstriction would reduce delivery of the antidote to the extravasation site, compromising its effectiveness. The 15-minute interval allows local circulation to recover sufficiently for dexrazoxane to reach the injured tissue .

Watch out! Keeping cold packs on throughout the dexrazoxane infusion is incorrect because it impairs antidote distribution. Applying cold only after the infusion is also incorrect because the initial cold application is needed immediately to limit drug spread.

Sequence of nursing actions

The correct sequence is: apply cold packs immediately after extravasation is identified, keep them in place for the recommended duration (typically 60–90 minutes total, with intermittent removal to prevent cold injury), then remove them at least 15 minutes before initiating dexrazoxane. This balances the need for early vasoconstriction with the need for adequate antidote delivery.

Timing	Action	Rationale
Immediately after extravasation	Apply cold packs to the site	Vasoconstriction limits drug spread and reduces tissue uptake
During initial management	Continue cold application intermittently	Maintains localized containment of the vesicant
At least 15 minutes before dexrazoxane	Remove cold packs	Allows vasodilation so the antidote can reach affected tissue
During dexrazoxane infusion	No cold packs in place	Prevents impaired antidote distribution from ongoing vasoconstriction

Clinical application for nursing licensure exams

This question tests understanding of drug-specific extravasation management and the interaction between local thermal therapy and systemic antidote administration. The distractors reflect common errors: applying heat to an anthracycline, leaving cold packs in place during antidote infusion, or delaying cold application until after the antidote is given. The correct answer integrates both the immediate local intervention and the timing required for effective antidote therapy ^[3].